Showing 341 - 360 results of 21,342 for search '(( significantly improving decrease ) OR ( significant decrease decrease ))', query time: 0.46s Refine Results
  1. 341
  2. 342
  3. 343
  4. 344

    Loxoprofen and SB225002 administration decreased sound stress exposure-induced hyperalgesia. by Satoka Kasai (3861115)

    Published 2025
    “…Mice treated with loxoprofen (500 mg/kg) or SB225002 (3 mg/kg) showed significantly decreased response times to the filament compared to Stress + saline group (Stress + loxoprofen (500 mg/kg), 30 min after administration, **<i>P</i> < 0.01, 60 min after administration, ***<i>P</i><i> <i><</i> </i>0.001; Stress + SB225002 (3 mg/kg), 60 min after administration, *<i>P</i> < 0.05). 2-way ANOVA <i>post-hoc</i> Bonferroni test. …”
  5. 345

    Table 1_Decreased neuronal excitability in hypertriglyceridemia hamsters with acute seizures.docx by Qiuyue Shen (20373266)

    Published 2024
    “…Following seizure induction, free palmitic acid levels in the frontal cortex dialysate significantly decreased, while the expression of palmitoyl acyltransferase 14 (ZDHHC14) in the frontal cortex tissue was higher in Apoc2<sup>−/−</sup> hamsters than in wild-type hamsters. …”
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  11. 351

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  12. 352

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  13. 353

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  14. 354

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  15. 355

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  16. 356

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  17. 357

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
  18. 358
  19. 359
  20. 360